Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease

This animal study investigated the effects of liraglutide, a GLP-1 receptor agonist used for type 2 diabetes, on cognitive function and neuropathology in a mouse model of Alzheimer's disease (AD). Aged APP/PS1 transgenic mice treated with liraglutide for two months showed a 33% reduction in amyloid plaque load, a 30%